Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).

被引：0

作者：

Ring, Alistair E.

Moretti, Laura

Afshari-Mehr, Angelica

Wardley, Andrew M.

Kilburn, Lucy

Gurel, Bora

MacPherson, Iain R.

Baird, Richard D.

Martin, Sue

Pearson, Alex

Roylance, Rebecca

Winter, Matthew

Dunne, Kathryn

Copson, Ellen

Hickish, Tamas

Stephens, Peter

Burcombe, Russell J.

Randle, Katrina

Bliss, Judith

Turner, Nicholas C.

机构：

[1] Royal Marsden NHS Fdn Trust, Surrey, England

[2] Inst Canc Res, Clin Trials & Stat Unit, London, England

[3] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England

[4] Outreach Res & Innovat Grp, Manchester, England

[5] Inst Canc Res, London, England

[6] Beatson West Scotland Canc Ctr, Glasgow, Scotland

[7] Canc Res UK, Cambridge Ctr, Cambridge, England

[8] Univ Coll London Hosp NHS Fdn Trust, London, England

[9] Univ Coll London Hosp, Biomed Res Ctr, NIHR, London, England

[10] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, England

[11] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England

[12] Univ Southampton, Southampton, England

[13] Royal Bournemouth Hosp, Bournemouth, England

[14] Poole Gen Hosp, Bournemouth, England

[15] Royal Devon & Exeter Hosp, Exeter, England

[16] Maidstone & Tunbridge Wells NHS Trust, Maidstone, Kent, England

[17] Independent Canc Patients Voice, London, England

[18] Royal Marsden Hosp, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1024

引用

页数：1

共 50 条

[21] Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
Cristiano de Pádua Souza
Ana Suellen Barroso Carneiro
Ana Cecília de Oliveira Lessa
Domício Carvalho Lacerda
Carlos Eduardo Paiva
Marina Moreira Costa Zorzetto
Ana Julia Aguiar de Freitas
Iara Viana Vidigal Santana
Marco Antonio de Oliveira
Edenir Inêz Palmero
Márcia Maria Chiquitelli Marques
Tomás Reinert
Breast Cancer Research and Treatment, 2023, 202 : 57 - 65
[22] Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
Souza, Cristiano de Padua
Carneiro, Ana Suellen Barroso
Lessa, Ana Cecilia de Oliveira
Lacerda, Domicio Carvalho
Paiva, Carlos Eduardo
Zorzetto, Marina Moreira Costa
de Freitas, Ana Julia Aguiar
Santana, Iara Viana Vidigal
de Oliveira, Marco Antonio
Palmero, Edenir Inez
Marques, Marcia Maria Chiquitelli
Reinert, Tomas
BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (01) : 57 - 65
[23] A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes
Yonemori, Kan
Shimomura, Akihiko
Yasojima, Hiroyuki
Masuda, Norikazu
Aogi, Kenjiro
Takahashi, Masato
Naito, Yoichi
Shimizu, Satoru
Nakamura, Rikiya
Hashimoto, Jun
Yamamoto, Harukaze
Hirakawa, Akihiro
Michimae, Hirofumi
Hamada, Akinobu
Yoshida, Teruhiko
Sukigara, Tamie
Tamura, Kenji
Fujiwara, Yasuhiro
EUROPEAN JOURNAL OF CANCER, 2019, 109 : 84 - 91
[24] Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer
Barnato, Sara E.
Jeruss, Jacqueline Sara
Bethke, Kevin P.
Hansen, Nora M.
Khan, Seema Ahsan
Von Roenn, Jamie H.
Rosen, Steven T.
Gradishar, William John
Siziopikou, Kalliopi P.
Meservey, Caitlin
Kaklamani, Virginia G.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[25] Concurrent Olaparib with Radiotherapy in Patients with Triple Negative Breast Cancer: Final Results of the RADIOPARP Phase 1 Trial
Loap, P.
Loirat, D.
Berger, F.
Rodrigues, M.
Bazire, L.
Pierga, J. Y.
Vincent-Salomon, A.
Laki, F.
Boudali, L.
Raizonville, L.
Mosseri, V.
Jochem, A.
Diallo, M.
Stern, M. H.
Fourquet, A.
Kirova, Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S43 - S44
[26] A phase one trial of olaparib with radiation therapy in patients with triple negative breast cancer: RADIOPARP
Kirova, Youlia M.
Loirat, Delphine
Berger, Frederique
Rodrigues, Manuel
Bazire, Louis
Chilles, Anne
Pierga, Jean Yves
Ricci, Francesco
Sablin, Marie Paule
Salomon, Anne Vincent
Laki, Fatima
Bertrand, Claire
Ezzili, Cyrine
Raizoville, Laurence
Mosseri, Veronique
Neffati, Souhir
Ezzalfani, Monia
Fourquet, Alain
CANCER RESEARCH, 2020, 80 (04)
[27] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
Jieqiong Liu
Ying Wang
Zhenluan Tian
Ying Lin
Hengyu Li
Zhaowen Zhu
Qiang Liu
Shicheng Su
Yinduo Zeng
Weijuan Jia
Yaping Yang
Shengqiang Xu
Herui Yao
Wen Jiang
Erwei Song
Nature Communications, 13
[28] randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
Chen, Nan
Saha, Poornima
Rampurwala, Murtuza M.
Kamaraju, Sailaja
Hahn, Olwen Mary
Howard, Frederick Matthew
Fleming, Gini F.
Matossian, Margarite
Freeman, Jincong Q.
Karrison, Theodore
Conzen, Suzanne D.
Nanda, Rita
Stringer-Reasor, Erica Michelle
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
Chen, Nan
Matossian, Margarite
Saha, Poornima
Rampurwala, Murtuza
Kamaraju, Salaija
Hahn, Olwen
Howard, Frederick M.
Fleming, Gini F.
Freeman, Jincong Q.
Karrison, Theodore
Conzen, Suzanne
Nanda, Rita
Stringer-Reasor, Erica M.
BREAST CANCER RESEARCH AND TREATMENT, 2025, : 111 - 119
[30] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
Liu, Jieqiong
Wang, Ying
Tian, Zhenluan
Lin, Ying
Li, Hengyu
Zhu, Zhaowen
Liu, Qiang
Su, Shicheng
Zeng, Yinduo
Jia, Weijuan
Yang, Yaping
Xu, Shengqiang
Yao, Herui
Jiang, Wen
Song, Erwei
NATURE COMMUNICATIONS, 2022, 13 (01)

← 1 2 3 4 5 →